BioSig Technologies' Natasha Drapeau joined Proactive to discuss the company's feasibility study with Haifa, Israel-based Technion Research & Development Foundation Ltd. Drapeau says under the terms of the program, the ECG signals supplied by the PURE EP System, the company’s signal processing technology for arrhythmia care, will be analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation procedures.
BioSig Technologies discusses significance of AI Development Program with Technion
